Agilent Q3 Revenues Slide 4 Percent; Beats Analyst Estimates on Top, Bottom Lines | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Wednesday that revenues for its fiscal third quarter shrank 4 percent year over year, although the Diagnostics and Genomics segment saw revenues grow 54 percent.

The company brought in a total of $1.65 billion for the three months ended July 31, down from $1.72 billion a year ago, but narrowly edging out the average Wall Street estimate of $1.64 billion.

Orders were down 4 percent year over year to $1.60 billion from $1.66 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.